Navigation Links
Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Date:3/18/2008

DEERFIELD, Ill., March 18 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that its Board of Directors has approved the repurchase of an additional $2 billion of the company's common stock to be executed upon completion of the company's existing share repurchase authorization.

Baxter has less than $700 million of remaining authorization under its previous $2 billion share repurchase program that was authorized in March 2007. Shares will be repurchased in the open market at times and amounts determined by management based on its evaluation of market conditions and other factors.

In 2007, Baxter returned more than $2.5 billion to shareholders through both share repurchases and dividends. The company repurchased 34 million shares of common stock, for approximately $1.9 billion, and paid dividends totaling $704 million.

"We remain confident in our ongoing ability to generate strong cash flows," said Robert M. Davis, chief financial officer. "We expect to return significant value to shareholders through a disciplined approach to capital allocation and financial management, while accelerating our investment in R&D and new business development opportunities that position us for future growth."

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning the company's expected cash flows, investments in R&D, accelerating business development activities and share repurchases and investments. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company's ability to identify and execute on business development and R&D opportunities; continued strength in the company's financial position, including cash flows; alternative uses of funds including, but not limited to dividends, business development transactions, and other investments in the company's businesses; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.


'/>"/>
SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. KGI Elects Three New Members to Board of Trustees
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
5. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
6. BioLife Solutions Expands Scientific Advisory Board
7. NeurogesX Appoints New Director to the Board
8. Genstar Names Michael Hurt to Its Strategic Advisory Board
9. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
10. Bruce Pasternack Elected to Codexis Board
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 2017 , ... Proscia Inc. , a data solutions ... whole slide imaging solutions, are hosting a pre-conference workshop at the Digital ... Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David West Jr., and ...
(Date:9/20/2017)... ... 2017 , ... RoviSys, a leading independent provider of comprehensive ... an office in Taipei, Taiwan. This new location allows RoviSys to better support ... in the region. Located in the Neihu area of Taipei, the office allows ...
(Date:9/19/2017)... , ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. ... PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and ... They bonded over an interest in the potential of stem cell therapy and a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical Services, ... of its 2017 Science Student Award. The scholarship program is dedicated to helping ... service defray the costs of obtaining their science education. , Avomeen began the ...
Breaking Biology Technology:
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):